Our services are spread out of the simple service to the partnership project and are applicable
to various industrial domains.
Our application fields are in narrow link with the biotechnologies and more particularly the white biotechnologies. These are used for industrial applications using biological systems as alternative for the classic chemical processes. Our services are thus applicable to very diversified sectors such as those of the polymers, fuels, solvents, the construction, textile industry and in all domains where the used products present a chemical dominant:
In these business sectors, we can propose to you solutions by enzymatic engineering.
OUR SERVICES, AT THE INTERFACE OF OUR THREE EXPERTISES AREAS
- Analysis of enzymatic activities
- Evaluation of inhibitors
- In vitro post-translation modifications
- Enzymatic synthesis of oligosaccharides
- Research in databases for an candidate enzyme identification
- Targeted gene cloning, random and rational mutagenesis, directed evolution
- Medium throughput screening
- Recombinantes proteins production
GLYCOM : Glycom is a privately held company founded in 2005 in Copenhagen, Denmark whose focus is to synthesize and commercialize human milk oligosaccharides (HMOs) along with their precursors and intermediates.
PEACCEL : PEACCEL is a service company specialized in protein engineering and design and synthetic biology. The company provides predictive product discovery solutions to biotech & pharmaceutical companies.
IMPACT : Molecular Interactions Activities Puces - is dedicated to functional proteomics, with major foci on protein expression profiling and biological activity–based molecular screening. Its specificities and services address two major biotechnological areas of interest for academic and industrial laboratories: Drug discovery and Biomanufacturing.
GLYCO-OUEST : GlycoOuest is an inter-regional emergent network of research on the glycosciences which gathers 14 laboratories of Brittany and Pays de la Loire. It is an interdisciplinary network the scientific fallout from which affects sectors of health, food-processing industry, feed, plant or still biomaterials.
PUBLICATIONS (most recent...)
Design of an α-L-transfucosidase for the synthesis of fucosylated HMOs. Saumonneau A, Champion E, Peltier-Pain P, Molnar-Gabor D, Hendrickx J, Tran V, Hederos M, Dekany G, Tellier C. Glycobiology. 2015 Nov 17. pii: cwv099.
Enhancing the chemoenzymatic synthesis of arabinosylated xylo-oligosaccharides by GH51 α-l-arabinofuranosidase. Arab-Jaziri F, Bissaro B, Tellier C, Dion M, Fauré R, O'Donohue MJ. Carbohydr Res. 2015 Jan 12;401:64-72.
Semi-rational approach for converting a GH36 α-glycosidase into an α-transglycosidase. Teze D, Daligault F, Ferrières V, Sanejouand YH, Tellier C. Glycobiology. 2014 Nov 13
De novo design of a trans-β-N-acetylglucosaminidase activity from a GH1 β-glycosidase by mechanism engineering. André-Miral C, Koné FM, Solleux C, Grandjean C, Dion M, Tran V, Tellier C. Glycobiology. 2014 Nov 4.
Semi-rational approach for converting a GH1 β-glycosidase into a β-transglycosidase. Teze D, Hendrickx J, Czjzek M, Ropartz D, Sanejouand YH, Tran V, Tellier C, Dion M. Protein Eng Des Sel. 2014 Jan;27(1):13-9.
Engineering transglycosidase activity into a GH51 α-l-arabinofuranosidase. Arab-Jaziri F, Bissaro B, Dion M, Saurel O, Harrison D, Ferreira F, Milon A, Tellier C, Fauré R, O'Donohue MJ. N Biotechnol. 2013 Jun 25;30(5):536-44.
Alkoxyamino glycoside acceptors for the regioselective synthesis of oligosaccharides using glycosynthases and transglycosidases. Teze D, Dion M, Daligault F, Tran V, André-Miral C, Tellier C. Bioorg Med Chem Lett. 2013 Jan 15;23(2):448-51.
Rational design of a GH1 beta-glycosidase to prevent self-condensation during the transglycosylation reaction. Tran V, Hoffmann L, Rabiller C, Tellier C, Dion M. Protein Eng Des Sel. 2010 Jan;23(1):43-9.
Engineering of glucoside acceptors for the regioselective synthesis of beta-(1->3)-disaccharides with glycosynthases. Marton Z, Tran V, Tellier C, Dion M, Drone J, Rabiller C. Carbohydr Res. 2008 Nov 24;343(17):2939-46.